Telenet Turns to Benu Networks to Deliver Cloud-based Managed Business Services to the SOHO/SME Markets
Benu Networks, a leading provider of innovative virtual network solutions that enable service providers to rapidly create and deliver next generation IP services, today announced that Telenet, the largest provider of cable broadband services in Belgium, has selected their Virtual Service Edge (VSE) platform to enable the rapid delivery of tailored, managed service offerings for the small office/home office (SOHO) and small-to-medium enterprise (SME) markets. Telenet’s managed offerings address key business priorities such as guest connectivity, device level visibility, and security by supplying SOHO/SME customers with convenient IT support and cybersecurity at highly affordable rates.
Telenet recognized that SOHO/SME customers, which account for 99.8% of Belgium enterprises as reported by Eurostat, wanted a service customized to their business routine and activities. With Telenet’s new Wi-Fi Business offering, SOHOs/SMEs can easily set up multiple networks that are public for patrons and private for employees. A customized, template-driven, user portal empowers the small business manager to enhance engagement with patrons in multiple areas, including Facebook check in, loyalty programs, and targeted promotions by using the analytical data collected. It enables better network monitoring of bandwidth, time usage, and allows for “time of day” restrictions. In addition, the service is in line with the new privacy guidelines that will come into effect in May 2018. Telenet’s new Wi-Fi Business service will be sold through the Telenet Business department which serves the business market in Belgium and Luxembourg.
“After an exhaustive selection process, Telenet is pleased to have chosen Benu Networks’ highly flexible architecture to deliver our new Wi-Fi Business service,” stated Stijn Vander Plaetse, Vice President, Product & Marketing, Telenet Business. “By moving key network functions to the cloud, this ingenious solution enables us to add new services rapidly and efficiently - seamlessly on top of our existing infrastructure. With the most compelling return on investment analysis, Benu Networks’ solution future proofed our network by delivering a single platform that supports the effortless launch of additional services going forward.”
Telenet utilizes Benu Networks’ Virtual Service Edge (VSE) platform, which leverages existing customer premises equipment (CPE)/IT infrastructure, to provide the new managed service. The VSE is a virtual software solution running on VMware network functions virtualization infrastructure (NFVI), and supports multiple services simultaneously. The VSE virtualizes complex CPE network functions, thereby transforming the service provider’s edge into a next generation, service delivery network to enable per device policy enforcement, visibility, and service stitching. This solution empowers Telenet to win within a highly competitive market with the service agility on par with over-the-top (OTT) providers, but with greater customer satisfaction and quality of experience (QoE) controls.
“We are pleased that VMware NFVi was chosen as the virtualization platform of choice by Benu Networks and Telenet,” said Honore LaBourdette, Vice President, Global Market Development, VMware. “Both companies have adopted VMware NFVi to enable digital transformation, and can benefit from a cost-effective deployment of next-generation services.”
“Benu Networks is thrilled to partner with Telenet Business to provide them the opportunity to address a critical market need with these vital business services for the SOHO/SME market,” said Mads Lillelund, CEO, Benu Networks. “Our Virtual Service Edge solution provides Telenet with the ability to rapidly address future market needs by launching additional revenue generating services from the platform - a critical requirement to successfully compete in today’s high-growth, IT cloud services marketplace.”
About Benu Networks: Benu Networks’ carrier-class Virtual Service Edge (VSE) software platform enables the rapid creation and delivery of next generation IP services over a converged infrastructure, and empowers service providers to increase revenue, expand market leadership, and meet the dynamic needs of their business, residential and mobile customers. For more information, please visit the Benu Networks website: www.benunetworks.com Follow us on Twitter @benunets.
VMware is a registered trademark of VMware, Inc. in the United States and other jurisdictions. All other marks and names mentioned herein may be trademarks of their respective companies.
Kelly Friedland, +1 781-640-4864
Director of Marketing
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu